Alirocumab

阿利西尤单抗

Report date: 2026/04/14 20:00:15
First In Class

Base Information

Drug NameAlirocumab
Drug Alias Name阿利苏单抗Anti-PCSK9 monoclonal antibodyAnti-proprotein convertase subtilisin kexin type 9 monoclonal antibody阿利人单抗Alirocumabum +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaIschemic StrokeHomozygous familial hypercholesterolemia +[24] 
Global Approved IndicationsHypercholesterolemiaDyslipidemiasAtherosclerosis
Approved Indications in ChinaHypercholesterolemiaDyslipidemiasAtherosclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2015/07/24
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofiRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis GroupeUniversity Of California San FranciscoChang Gung University +[9] 
Inactive CompaniesUtah State UniversityWashington University School Of MedicineBaylor Research Institute Llc +[6] 
Active IndicationsIschemic StrokeHomozygous familial hypercholesterolemiaDrinking Behavior +[19] 
Inactive IndicationsHeterozygous familial hypercholesterolemiaHemorrhageCoronary Disease +[5] 

Other Information

ATC CodeC10AX14
Related LinksWikipediaDrugBankKEGG